Premium
O1–06–01: Immunization with Aβ1–6 coupled to the virus–like particle Qβ (CAD106) efficiently removes β–amyloid without inducing Aβ–reactive T–cells
Author(s) -
Staufenbiel Matthias,
Wiederhold Karl-Heinz,
Tissot Alain C.,
Frey Peter,
Fulurija Alma,
Hiestand Peter,
Jennings Gary T.,
Lüönd Rainer,
Mayer Peter,
Ortmann Rainer,
Stoeckli Markus,
Stumper Barbara,
Zurini Mauro,
Mir Anis,
Bachmann Martin F.,
Christoph Wiessner
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.061
Subject(s) - epitope , adjuvant , immunization , antibody , amyloid (mycology) , virology , t cell , genetically modified mouse , peptide , peptide vaccine , microbiology and biotechnology , biology , transgene , chemistry , immunology , medicine , immune system , pathology , biochemistry , gene
in different countries. Results: In the base-case scenario, the worldwide cost of informal care is estimated at 92 billion US$, which together with the estimate of direct cost results in a total worldwide cost of dementia of 248 billion US$. 62% of the demented live in the developing countries which account for 16% of the total costs. In a sensitivity analysis several alternative estimates are presented. Conclusions: All assumptions include both uncertainties and variability. However, this study demonstrates that the worldwide costs of dementia are substantial. Particularly the future increase of people with dementia in the developing countries presents is a great challenge.